Schechter Investment Advisors LLC Has $710,000 Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Schechter Investment Advisors LLC lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 7,681 shares of the biopharmaceutical company’s stock after purchasing an additional 243 shares during the quarter. Schechter Investment Advisors LLC’s holdings in Gilead Sciences were worth $710,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of GILD. Swedbank AB grew its position in shares of Gilead Sciences by 10.2% in the 3rd quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company’s stock valued at $171,672,000 after purchasing an additional 189,622 shares during the period. Chicago Partners Investment Group LLC grew its position in shares of Gilead Sciences by 8.6% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 6,850 shares of the biopharmaceutical company’s stock valued at $598,000 after purchasing an additional 540 shares during the period. Harbor Capital Advisors Inc. grew its position in shares of Gilead Sciences by 2.6% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 27,005 shares of the biopharmaceutical company’s stock valued at $2,264,000 after purchasing an additional 695 shares during the period. PDS Planning Inc grew its position in shares of Gilead Sciences by 10.6% in the 3rd quarter. PDS Planning Inc now owns 4,500 shares of the biopharmaceutical company’s stock valued at $377,000 after purchasing an additional 433 shares during the period. Finally, Moloney Securities Asset Management LLC grew its position in shares of Gilead Sciences by 5.4% in the 3rd quarter. Moloney Securities Asset Management LLC now owns 25,975 shares of the biopharmaceutical company’s stock valued at $2,178,000 after purchasing an additional 1,326 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

GILD has been the subject of a number of recent research reports. Barclays upped their price target on Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Thursday, November 7th. Bank of America reaffirmed a “buy” rating and set a $109.00 price target on shares of Gilead Sciences in a research report on Tuesday, December 10th. Citigroup initiated coverage on Gilead Sciences in a research report on Thursday, November 14th. They set a “buy” rating and a $125.00 price target for the company. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $80.00 price target on shares of Gilead Sciences in a research report on Wednesday, December 11th. Finally, DZ Bank raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price objective for the company in a report on Thursday, February 13th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $102.76.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the sale, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold 293,356 shares of company stock worth $29,166,240 in the last 90 days. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Down 1.1 %

GILD stock opened at $114.74 on Wednesday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The stock has a market capitalization of $143.00 billion, a price-to-earnings ratio of 310.11, a PEG ratio of 0.71 and a beta of 0.21. The business’s fifty day moving average price is $98.28 and its two-hundred day moving average price is $90.74. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $117.39.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a dividend of $0.79 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 annualized dividend and a yield of 2.75%. Gilead Sciences’s dividend payout ratio (DPR) is presently 854.05%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.